FDA Approves CISATRACURIUM BESYLATE — Somerset Therapeutics, LLC

Somerset Therapeutics received final FDA approval on February 20 to market cisatracurium besylate (ANDA 206791), positioning the company to capitalize on a rapidly growing market for intravenous paralytics that offline competitors are struggling to serve. This clearance allows Somerset to leverage Medicare Part B reimbursement, offering a differentiated product capable of capturing significant outsized sales volume over the next five years.